Oxford Events, the new replacement for OxTalks, will launch on 16th March. From now until the launch of Oxford Events, new events cannot be published or edited on OxTalks while all existing records are migrated to the new platform. The existing OxTalks site will remain available to view during this period.
From 16th, Oxford Events will launch on a new website: events.ox.ac.uk, and event submissions will resume. You will need a Halo login to submit events. Full details are available on the Staff Gateway.
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have been hailed as a major scientific breakthrough by several stakeholders. These medications display neuroprotective/anti-inflammatory and dopamine-regulating activities involved in cognitive, addictive, psychotic, and mood disorder. Industry and most major academic institutions are competing to investigate GLP-1RAs’ repurposing potential for all these conditions.
In this talk, I will report on available pre-clinical and clinical studies about the putative neuropsychiatric effects of GLP-1RAs – whether positive or negative, and consider putative mechanisms of action. I will then present an epidemiological investigation completed within my laboratory about the risk of neurological and psychiatric outcomes in T2DM patients using the GLP-1RAs semaglutide, where we found that the use of this medication may be associated with a lower risk of cognitive deficit and nicotine use disorders. I will discuss how evidence from this study has been used to inform the design of an experimental medicine trial in healthy volunteers, which assesses the potential neuropsychological bases of its effect, and present our findings across several cognitive domains.
Finally, I will provide perspectives about the further development of GLP-1RA-based compounds, considering both its promises and pitfalls, including our next working steps in Oxford.
Riccardo De Giorgi is a Clinical Lecturer at the University of Oxford, Department of Psychiatry, and ST6 at Health Education England-Thames Valley, Oxford Health NHS Foundation Trust. He is interested in neuropsychopharmacology and evidence-based treatment of mental illness. He works on evidence synthesis, epidemiological, and experimental medicine studies to investigate repurposing opportunities for drugs with immune-metabolic activity (e.g., statins, GLP-1RAs) in cognitive and mental disorders.
This seminar is hosted in person in the Department of Psychiatry, Seminar Room and online. To join online, please use the details below:
zoom.us/j/92620728590?pwd=s1JefrGff6bN0nZZcHSTBkCw8Z1RlT.1
Meeting ID: 926 2072 8590
Passcode: 196542
